Beigene Ltd
ONC335.170USD
+2.460+0.74%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
34.11BMarket Cap
497.60P/E TTM
More Details of Beigene Ltd Company
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Beigene Ltd Info
Ticker SymbolONC
Company nameBeOne Medicines AG
IPO date- -
CEOMr. John Victor Oyler
Number of employees11000
Security typeOrdinary Share
Fiscal year-end- -
Addressc/o BeOne Medicines I GmbH
CityBASEL
Stock exchangeThe Toronto Stock Exchange
CountrySwitzerland
Postal code4051
Phone41616851900
Website
Ticker SymbolONC
IPO date- -
CEOMr. John Victor Oyler
Company Executives of Beigene Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marcello Damiani
Mr. Marcello Damiani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marcello Damiani
Mr. Marcello Damiani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Product
1.28B
97.39%
BRUKINSA
949.84M
72.21%
Tislelizumab
193.52M
14.71%
XGEVA
81.32M
6.18%
BLINCYTO
25.59M
1.95%
Other
-1.22B
-92.44%
By RegionUSD
Name
Revenue
Proportion
United States
694.43M
52.80%
China
432.92M
32.91%
Europe
152.38M
11.59%
ROW
35.56M
2.70%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
1.28B
97.39%
BRUKINSA
949.84M
72.21%
Tislelizumab
193.52M
14.71%
XGEVA
81.32M
6.18%
BLINCYTO
25.59M
1.95%
Other
-1.22B
-92.44%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
Other
62.04%
Shareholders
Shareholders
Proportion
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
Other
62.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.52%
Corporation
17.28%
Hedge Fund
8.21%
Investment Advisor/Hedge Fund
3.74%
Sovereign Wealth Fund
0.92%
Research Firm
0.57%
Pension Fund
0.05%
Family Office
0.02%
Family Office
0.02%
Other
51.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
565
40.04M
36.51%
-2.11M
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Amgen Inc
18.94M
17.27%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.02%
--
--
Jun 30, 2025
PRIMECAP Management Company
5.09M
4.64%
+32.77K
+0.65%
Jun 30, 2025
Capital International Investors
4.89M
4.45%
-205.96K
-4.05%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.41M
3.11%
+51.63K
+1.54%
Jun 30, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
Jun 30, 2025
Temasek Holdings Pte. Ltd.
1.01M
0.92%
+16.71K
+1.68%
Jun 30, 2025
T. Rowe Price International Ltd
931.90K
0.85%
-369.24K
-28.38%
Jun 30, 2025
Invus Public Equities Advisors, LLC
509.99K
0.47%
+11.30K
+2.27%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
VanEck Biotech ETF
4.69%
First Trust NYSE Arca Biotechnology Index Fund
4.23%
Tema Oncology ETF
2.89%
Global X Aging Population ETF
2.58%
Virtus LifeSci Biotech Products ETF
2.05%
iShares Biotechnology ETF
2.01%
Innovator IBD 50 Fund ETF
1.39%
ProShares Ultra Nasdaq Biotechnology
1.18%
Invesco Nasdaq Biotechnology ETF
1.16%
Capital Group Global Equity ETF
0.87%
View more
VanEck Biotech ETF
Proportion4.69%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.23%
Tema Oncology ETF
Proportion2.89%
Global X Aging Population ETF
Proportion2.58%
Virtus LifeSci Biotech Products ETF
Proportion2.05%
iShares Biotechnology ETF
Proportion2.01%
Innovator IBD 50 Fund ETF
Proportion1.39%
ProShares Ultra Nasdaq Biotechnology
Proportion1.18%
Invesco Nasdaq Biotechnology ETF
Proportion1.16%
Capital Group Global Equity ETF
Proportion0.87%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Beigene Ltd?
The top five shareholders of Beigene Ltd are:
Amgen Inc holds 18.94M shares, accounting for 17.27% of the total shares.
Baker Bros. Advisors LP holds 8.80M shares, accounting for 8.02% of the total shares.
PRIMECAP Management Company holds 5.09M shares, accounting for 4.64% of the total shares.
Capital International Investors holds 4.89M shares, accounting for 4.45% of the total shares.
Fidelity Management & Research Company LLC holds 3.41M shares, accounting for 3.11% of the total shares.
Amgen Inc holds 18.94M shares, accounting for 17.27% of the total shares.
Baker Bros. Advisors LP holds 8.80M shares, accounting for 8.02% of the total shares.
PRIMECAP Management Company holds 5.09M shares, accounting for 4.64% of the total shares.
Capital International Investors holds 4.89M shares, accounting for 4.45% of the total shares.
Fidelity Management & Research Company LLC holds 3.41M shares, accounting for 3.11% of the total shares.
What are the top three shareholder types of Beigene Ltd?
The top three shareholder types of Beigene Ltd are:
Amgen Inc
Baker Bros. Advisors LP
PRIMECAP Management Company
Amgen Inc
Baker Bros. Advisors LP
PRIMECAP Management Company
How many institutions hold shares of Beigene Ltd (ONC)?
As of 2025Q3, 565 institutions hold shares of Beigene Ltd, with a combined market value of approximately 40.04M, accounting for 36.51% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -21.03%.
What is the biggest source of revenue for Beigene Ltd?
In FY2025Q2, the Product business generated the highest revenue for Beigene Ltd, amounting to 1.28B and accounting for 97.39% of total revenue.
